title: [Cost-effectiveness of the addition of acarbose to the treatment of patients with type-2 diabetes in Spain].
abstract: OBJECTIVE
  To assess the cost-effectiveness of the addition of acarbose to existing treatment in patients with type 2 diabetes mellitus (DM2) in Spain.
  
  
  METHODS
  The CORE Diabetes Model (a published and validated computer simulation model) was used to project long-term clinical and cost outcomes in DM2. Transition probabilities and risk adjustments were derived from published sources. Treatment effects and baseline cohort characteristics were based on a meta-analysis. Direct costs were retrieved from published sources and projected over patient lifetimes from the perspective of the Spanish National Health Service. Costs and clinical benefits were discounted at 3% per year. Sensitivity analyses were performed.
  
  
  RESULTS
  Acarbose treatment was associated with improved life expectancy (0.23 years) and quality-adjusted life years (QALY) (0.21 years). Direct costs were on average euro 468 per patient more expensive with acarbose than with placebo. The incremental cost-effectiveness ratios were euro 2,002 per life year gained and euro 2,199 per QALY gained. An acceptability curve showed that with a willingness to pay euro 20,000, which is generally accepted to represent very good value for money, acarbose treatment was associated with a 93.5% probability of being cost-effective.
  
  
  CONCLUSIONS
  This long-term economic study showed that the addition of acarbose to existing therapy for DM2 was associated with improvements in life expectancy and QALYs in these patients.
authors.affiliation: Química Farmacéutica Bayer, S. A., Barcelona, España. carmen.pinol.cp@bayer.es
authors.forename: Carme
authors.initials: C
authors.lastname: Piñol
authors.forename: Stephane
authors.initials: S
authors.lastname: Roze
authors.forename: William
authors.initials: W
authors.lastname: Valentine
authors.forename: Thomas
authors.initials: T
authors.lastname: Evers
mesh_terms: D020909:Acarbose / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics* / Q000627:therapeutic use*; D008875:Middle Aged; D013030:Spain
chemical_list: D007004:Hypoglycemic Agents; D020909:Acarbose